参考文献
[1]BRIDGEWATER J, GALLE PR, KHAN SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma[J]. J Hepatol, 2014, 60(6): 1268-1289.
[2]BERGQUIST A, von SETH E. Epidemiology of cholangiocarcinoma[J]. Best Pract Res Clin Gastroenterol, 2015, 29(2): 221-232.
[3]RAZUMILAVA N, GORES GJ. Cholangiocarcinoma [J]. Lancet, 2014, 383(9935): 2168-2179.
[4]LUO X, YUAN L, WANG Y, et al. Survival outcomes and prognostic factors of surgical therapy for all potentially resectable intrahepatic cholangiocarcinoma: A large single-center cohort study[J]. J Gastrointest Surg, 2014, 18(3): 562-572.
[5]CHEN ZS, ZHOU XP, LIN PY, et al. Research progress in prognostic factors of intrahepatic cholangiocarcinoma[J]. Shanghai Med J, 2015, 38(3): 259-262. (in Chinese)
陈志升, 周学平, 林培艺, 等. 肝内胆管细胞癌预后因素的研究进展[J]. 上海医学, 2015, 38(3): 259-262.
[6]SAHA SK, ZHU AX, FUCHS CS, et al. Forty-year trends in cholangiocarcinoma incidence in the U.S.: Intrahepatic disease on the rise[J]. Oncologist, 2016, 21(5): 594-599.
[7]TORRE LA, BRAY F, SIEGEL RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
[8]LIU ZH, CHEN Z, MA LL, et al. Factors influencing the prognosis of patients with intrahepatic cholangiocarcinoma[J]. Acta Gastroenterol Belg, 2012, 75(2): 215-218.
[9]HUANG ZQ. Development direction of Hepatobiliary Surgery[J]. J Surg Theory Pract, 2011, 16(4): 329-331. (in Chinese)
黄志强. 肝胆管外科的发展方向[J]. 外科理论与实践, 2011, 16(4): 329-331.
[10]HWANG S, LEE YJ, SONG GW, et al. Prognostic impact of tumor growth type on 7th AJCC staging system for intrahepatic cholangiocarcinoma: A single-center experience of 659 cases[J]. J Gastrointest Surg, 2015, 19(7): 1291-1304.
[11]LORIA F, LORIA G, BASILE S, et al. Contrast-enhanced ultrasound appearances of enhancement patterns of intrahepatic cholangiocarcinoma: Corelation with pathological findings[J]. Updates Surg, 2014, 66(2): 135-143.
[12]ZHANG W, WANG TS, SHANG PZ, et al. Research progresses on diagnosis of cholangiocarcinoma[J]. J Hebei North Univ (Natural Science Edition), 2018, 34(10): 52-55, 60. (in Chinese)
张伟, 王铁山, 尚培中, 等. 胆管癌的诊断研究进展[J]. 河北北方学院学报 (自然科学版), 2018, 34(10): 52-55, 60.
[13]YUAN HX, WANG WP, CAO JY, et al. Value of contrast-enhanced ultrasound in preoperative evaluation for hilar cholangiocarcinoma[J/CD]. Chin J Med Ultrasound (Electronic edition), 2014, 11(5): 418-422. (in Chinese)
袁海霞, 王文平, 曹佳颖, 等. 超声造影在肝门部胆管癌术前评估中的应用价值[J/CD].中华医学超声杂志(电子版), 2014, 11(5): 418-422.
[14]WU XJ, DAN HJ, SUN L, et al. Characteristics of contrast-enhanced ultrasound in diagnosis of patients with intrahepatic cholangiocarcinoma[J]. J Prac Hepatol, 2018, 21(5): 803-804. (in Chinese)
武晓静, 丹海俊, 孙丽, 等. 肝内胆管细胞癌患者超声造影表现特征分析[J]. 实用肝脏病杂志, 2018, 21(5): 803-804.
[15]YAMASAKI S. Intrahepatic cholangiocarcinoma: Macroscopic type and stage classification[J]. J Hepatobiliary Pancreat Surg, 2003, 10(4): 288-291.
[16]HUA XD, FU XB, HAO ZQ, et al. Computed tomographic diagnosis of intrahepatic cholangiocarcinoma[J]. Natl Med J China, 2014, 94(6): 449-451.(in Chinese)
华向东, 傅熙博, 郝志强, 等. 肝内胆管细胞癌的CT表现特征分析[J]. 中华医学杂志, 2014, 94(6): 449-451.
[17]JIA YC. CT diagnosis of intrahepatic mass-forming type cholangiocarcinoma [J]. Imaging Technol, 2016, 28(2): 9-12.(in Chinese)
贾玉昌. 肝内肿块型胆管细胞癌的CT诊断[J]. 影像技术, 2016, 28(2): 9-12.
[18]LUAN DG, NIU HD. Comprehensive diagnosis of intrahepatic peripheral cholangiocarcinoma by CT and MRI [J]. J Imag Res Med Appl, 2019, 3(16): 18-20. (in Chinese)
栾德广, 牛焕东. CT及MRI对肝内周围型胆管癌综合诊断[J]. 影像研究与医学应用, 2019, 3(16): 18-20.
[19]GU FM, WANG ZG, YANG Y, et al. Clinical value of Fluorine-18-fluorodeoxyglucose PET-CT examination in intrahepatic cholangiocarcinoma staging[J]. Chin J Dig Surg, 2019, 18(5): 499-505. (in Chinese)
顾方明, 汪珍光, 杨远, 等. 18氟-氟代脱氧葡萄糖PET-CT检查在肝内胆管癌分期中的临床价值[J]. 中华消化外科杂志, 2019, 18(5): 499-505.
[20]ZHANG J, WU YY, ZUO CJ, et al. Evaluation of the role of 18F-FDG PET/CT in the diagnosis of intrahepatic cholangiocarcinoma[J]. Diagn Imag Interv Radiol, 2016, 25(2): 161-166. (in Chinese)
张建, 吴仪仪, 左长京, 等. 18F-FDG PET/CT对肝内胆管癌的诊断价值研究[J]. 影像诊断与介入放射学, 2016, 25(2): 161-166.
[21]XIAO Y. The value of 18F-FDG-PETCT combined with CT enhanced scan in the diagnosis of intrahepatic cholangiocarcinoma[J]. J World Latest Med Inf, 2018, 18(67): 160-162. (in Chinese)
肖勇. 18F-FDG-PETCT显像结合CT增强扫描在肝内胆管癌诊断中的价值[J]. 世界最新医学信息文摘, 2018, 18(67): 160-162.
[22]COSTELLO JR, KALB B, CHUNDRU S, et al. MR imaging of benign and malignant biliary conditions[J]. Magn Reson Imaging Clin N Am, 2014, 22(3): 467-488.
[23]LIU NC. MRI diagnosis of intrahepatic cholangiocarcino.ma[J]. J Pract Med Imag, 2015, 16(3): 185-187. (in Chinese)
刘宁川. 肝内胆管癌的磁共振成像诊断价值[J]. 实用医学影像杂志, 2015, 16(3): 185-187
[24]SUN YL, ZHANG YC. Application of CT, MRCP and ERCP in diagnosis and treatment of hilar cholangiocarcinoma[J]. J Pract Med, 2010, 26(1): 97-99. (in Chinese)
孙玉亮, 张迎春. CT、MRCP及ERCP在肝门部胆管癌诊治中的应用[J]. 实用医学杂志, 2010, 26(1): 97-99.
[25]LI J. MRI features of highly differentiated intrahepatic cholangiocarcinoma[J]. China Digital Med, 2019, 14(1): 47-49. (in Chinese)
李杰. 高分化肿块型肝内胆管细胞癌的MRI特征[J]. 中国数字医学, 2019, 14(1): 47-49.
[26]ZHANG SS, SHAO WS, CAO YF, et al. CT and MRI in the diagnosis of intrahepatic peripheral cholangiocarcinoma[J]. Hebei Med, 2016, 22(5): 793-794. (in Chinese)
张松山, 邵文尚, 曹永峰, 等. CT及MRI对肝内周围型胆管癌综合诊断研究[J]. 河北医学, 2016, 22(5): 793-794.
[27]WEI DW. The value of spiral CT and MRI in the diagnosis of intrahepatic cholangiocarcinoma[J]. Imaging Technol, 2019, 31(1): 4-6. (in Chinese)
魏定伟. 螺旋CT和MRI诊断肝内胆管细胞癌的运用价值研究[J]. 影像技术, 2019, 31(1): 4-6.
[28]STUL KE, TISE ML, ALI Z, et al. Acuracy and reliability of measurements obtained from computed tomography 3D volume rendered images[J]. Forensic Sci Int, 2014, 238: 133-140.
[29]BGIN A, MARTEL G, LAPOINTE R, et al. Accuracy of preoperative automatic measurement of the liver volume by CT-scan combined to a 3D virtual surgical planning software (3DVSP)[J]. Surg Endosc, 2014, 28(12): 3408-3412.
[30]LI PP, WANG ZH, HUANG G, et al. Application of liver three-dimensional visualization technologies in the treatment planning of hepatic malignant tumor[J]. Chin J Surg, 2017, 55(12): 916-922.(in Chinese)
李鹏鹏, 王志恒, 黄罡, 等. 肝脏三维可视化技术在肝脏恶性肿瘤治疗规划中的应用研究[J]. 中华外科杂志, 2017, 55(12): 916-922.
[31]MALAGUARNERA G, PALADINA I, GIORDANO M, et al. Serum markers of intrahepatic cholangiocarcinoma[J]. Dis Markers, 2013, 34(4): 219-228.
[32]INCE AT, YILDIZ K, BAYSAL B, et al. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions[J]. Turk J Gastroenterol, 2014, 25(2): 162-169.
[33]MARUBASHI S, GOTOH K, TAKAHASHI H, et al. Prediction of the postoperative prognosis of intrahepatic cholangiocarcinoma (ICC): Importance of preoperatively- determined anatomic invasion level and number of tumors[J]. Dig Dis Sci, 2014, 59(1): 201-213.
[34]ZENG X, TAO H. Diagnostic and prognostic serum marker of cholangiocarcinoma (Review)[J]. Oncol Lett, 2015, 9(1): 3-8.
[35]ZHANG QF, LI YZ, LI JX. Diagnosis value of serum CA199, CA242 and CA724 in malignant tumors of digestive system[J]. J Shanxi Med Univ, 2007, 38(5): 430-432. (in Chinese)
张启芳, 李运泽, 李俊喜. 血清CA199、CA242和CA724含量对消化系恶性肿瘤的诊断价值[J]. 山西医科大学学报, 2007, 38(5): 430-432.
[36]MA WH. Diagnostic value of combined detection of serum CA199 and CEA in the diagnosis of cholangiocarcinoma[J/CD]. J Clin Med, 2016, 3(3): 577-578. (in Chinese)
马婉红. 血清CA199和CEA联合检测对胆管癌的诊断价值分析[J/CD]. 临床医药文献电子杂志, 2016, 3(3): 577-578.
[37]SHEN F, WANG K, YAN ZL, et al. Clinical efficacy and prognostic factors of liver resection for intrahepatic cholangiocarcinoma in 1370 patients[J]. Chin J Dig Surg, 2016, 15(4): 319-328. (in Chinese)
沈锋, 王葵, 阎振林, 等. 1370例肝内胆管细胞癌肝切除术的疗效及预后因素分析[J]. 中华消化外科杂志, 2016, 15(4): 319-328.
[38]DENG YW, ZHONG RH, XIE XY, et al. The clinical value of serum CA19-9 and CA125 in diagnosing of cholangiocarcinoma[J]. Lingnan J Emerg Med, 2016, 21(3): 251-252. (in Chinese)
邓雅文, 钟日辉, 谢晓英, 等. 血清肿瘤标志物CA19-9和CA125在胆管癌诊断中的价值[J]. 岭南急诊医学杂志, 2016, 21(3): 251-252.
[39]ZHANG GB, XU JH. Application of serum CA19-9, CA125 and CEA in diagnosis of serum AFP negative patients with intrahepatic cholangiocarcinoma[J]. J Prac Hepatol, 2017, 20(6): 740-743. (in Chinese)
张国柄, 徐江海. 联合CA19-9、CA125和CEA检测在AFP阴性的ICC鉴别诊断中的应用价值[J]. 实用肝脏病杂志, 2017, 20(6): 740-743.
[40]NISHIJIMA TF, MUSS HB, SHACHAR SS, et al. Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: A systematic review and meta-analysis[J]. Cancer Treat Rev, 2015, 41(10): 971-978.
[41]CHEN YQ, TIAN Q, GONG J, et al. Diagnostic value of neutrophil/lymphocyte ratio combined with CA19-9 for intrahepatic cholangiocarcinoma[J/CD]. Chin J Hepat Surg: Electronic Edition, 2019, 8(4): 358-361. (in Chinese)
陈亚琼, 田琪, 龚娇, 等. 中性粒细胞/淋巴细胞比值联合CA19-9对肝内胆管癌的诊断价值[J/CD]. 中华肝脏外科手术学电子杂志, 2019, 8(4): 358-361.
[42]CHEN YJ, SHANG CZ. Diagnosis and management of intrahepatic cholangiocarcinoma[J]. Chin J Pract Surg, 2015, 35(1): 43-45. (in Chinese)
陈亚进, 商昌珍. 肝内胆管细胞癌诊治策略[J]. 中国实用外科杂志, 2015, 35(1): 43-45.
[43]LI YL. Pathology(8th Edition)[M]. Beijing: People’s Health Press, 2013: 284. (in Chinese)
李玉林. 病理学(第八版)[M]. 北京:人民卫生出版社, 2013: 284.
[44]LI XP, LIU SL, JIANG B. Progress of molecular profiling of intrahepatic cholangiocarcinoma[J]. Chin J Gen Surg, 2019, 28(2): 219-226. (in Chinese)
李雪鹏, 刘苏来, 蒋波. 肝内胆管癌分子水平研究进展[J]. 中国普通外科杂志, 2019, 28(2): 219-226.
[45]FANG F, SONG TQ. Research progress associated with microRNAs in hepatocellular carcinoma[J]. Chin J Gen Surg, 2018, 27(7): 899-909. (in Chinese)
房锋, 宋天强. 微小RNA在肝细胞癌中的相关研究进展[J]. 中国普通外科杂志, 2018, 27(7): 899-909.
[46]WONG CM, TSANG FH, NG IO. Non-coding RNAs in hepatocellular carcinoma: Molecular functions and pathological implications[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(3): 137-151.